Liminatus Pharma, Inc. Class A Common Stock
LIMNLiminatus Pharma is a pre-clinical stage biopharmaceutical company focused on developing novel cancer therapies that leverage the body's immune system.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Liminatus Pharma is a pre-clinical stage biopharmaceutical company focused on developing novel cancer therapies that leverage the body's immune system. Its primary value proposition is a next-generation CD47 checkpoint inhibitor designed to target solid tumors while avoiding the common side effects of anemia and thrombocytopenia associated with earlier CD47 treatments. The company aims to establish a leadership position in immuno-oncology through both internal development and strategic in-licensing of differentiated therapeutic assets.
Liminatus is a pre-clinical developer seeking to differentiate itself through a next-generation CD47 antibody that avoids red blood cell binding, a major limitation of first-generation competitors.
Questions, answered.
- What is Liminatus Pharma, Inc. Class A Common Stock's market cap?
- Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market capitalization of $7.6M and trades on NASDAQ.
- Who are Liminatus Pharma, Inc. Class A Common Stock's competitors?
- Liminatus Pharma, Inc. Class A Common Stock's key competitors include Bristol-Myers Squibb, Regeneron, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Liminatus Pharma, Inc. Class A Common Stock partner with?
- Liminatus Pharma, Inc. Class A Common Stock's notable partners include InnoBation Bio Co. Ltd., GenScript ProBio, Charles River Laboratories, and others.
- What subsidiaries does Liminatus Pharma, Inc. Class A Common Stock have?
- Liminatus Pharma, Inc. Class A Common Stock's subsidiaries include Liminatus Pharma, LLC.
- Where is Liminatus Pharma, Inc. Class A Common Stock headquartered?
- Liminatus Pharma, Inc. Class A Common Stock is headquartered in United States of America. It has been publicly traded since 2025.